DF/HCC Prostate SPORE

DF/HCC 前列腺孢子

• 批准号: 10628270
• 负责人: Steven P. Balk
• 金额: $ 258.56万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10628270
• 关键词: Acceleration; Acute; Address; Androgen Receptor; Autopsy; Back; Basic Science; Biological; Biological Assay; Biological Markers; Biometry; Blood; Blood specimen; Cancer Biology; Cancer Center; Cancer Etiology; Caring; Cessation of life; Clinical; Clinical Investigator; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communication; Communities; Computational Biology; Dana-Farber Cancer Institute; Data; Dedications; Development; Diagnosis; Disease; Disease Resistance; EZH2 gene; Early Diagnosis; Early treatment; Ensure; Environment; Epigenetic Process; Fostering; Funding; General Hospitals; Genomics; Goals; Growth; Hospitals; Individual; Infrastructure; Institution; Israel; Laboratories; Laboratory Research; Lead; Machine Learning; Malignant Neoplasms; Malignant neoplasm of prostate; Massachusetts; Medical center; Mentors; Molecular; Morbidity - disease rate; Neoadjuvant Therapy; Newly Diagnosed; Pathology; Pathway interactions; Patient advocacy; Patients; Phenotype; Population Sciences; Pre-Clinical Model; Principal Investigator; Prognostic Marker; Prostate; Prostate Cancer therapy; Recruitment Activity; Research; Research Personnel; Resistance; Resistance development; Resources; Services; Specimen; Therapeutic; Tissues; Translating; Translational Research; Translations; United States; Work; Writing; anticancer research; bench to bedside; biomarker development; biomarker discovery; biomarker driven; cancer genomics; cancer initiation; career; castration resistant prostate cancer; clinical translation; cohort; combat; data sharing; deep learning; drug standard; epigenome; follow-up; high risk; improved; individualized medicine; innovation; insight; meetings; men; model development; mortality; next generation; next generation sequencing; novel; novel strategies; patient population; pre-clinical; precision medicine; precision oncology; preclinical study; programs; prostate cancer risk; repository; resistance mechanism; success; therapy resistant; translational approach; translational cancer research; translational scientist; tumor; tumor progression

PROJECT SUMMARY – OVERALL The Dana-Farber/Harvard Cancer Center (DF/HCC) Prostate SPORE seeks to improve the understanding and treatment of prostate cancer using a highly translational approach. The application consists of three Projects, three Cores, a Developmental Research Program and a Career Enhancement Program. The SPORE infrastructure will facilitate interactions and collaboration within our thriving community of basic, clinical, and population science researchers dedicated to prostate cancer research. Each project addresses a fundamental challenge that contributes to prostate cancer morbidity and mortality. Project 1 leverages tumor specimens from patients with high-risk prostate cancer treated with neoadjuvant therapies to understand how tumors respond and resist acute potent androgen receptor blockade and to develop novel strategies to improve cure rates and combat resistance. Project 2 will develop innovative strategies to target the epigenome in later stages of advanced castration resistant prostate cancer and will develop a first-in-field clinical trial focused on co-targeting EZH2 and PARP. Project 3 delves deep into biomarkers in localized prostate cancer, leveraging innovations in computation and biologically-guided deep learning, to deliver on precision cancer medicine in this disease state. The ability to understand why some localized prostate cancers are phenotypically aggressive and predict which localized prostate cancers will behave in this manner addresses a large clinical unmet need. Each of these projects combines elegant preclinical work with innovative clinical studies led by DF/HCC investigators. Core A, the Administrative Core, will be the center for scientific, fiscal and administrative oversight. It will lead efforts in planning and communication, and also house the Patient Advocacy Committee. Core A will ensure that the DF/HCC infrastructure supports the SPORE clinical and translational research efforts. Core B, the Biostatistics and Computational Biology core, will provide specialized expertise in biostatistics and the management of genomic and other next generation sequencing data and data sharing. Core C, the Biospecimen and Pathology Core, will maintain tissue/blood repositories for the SPORE projects as well as other investigators within the prostate cancer program. It will provide critical expertise and pathology services including next generation molecular assays and will help facilitate the use of fresh tumor specimens including rapid autopsies for patient derived model development to accelerate translational investigation. The Developmental Research and Career Enhancement Programs will identify and fund innovative projects that address basic, translational, and clinical research questions and unmet needs in prostate cancer and will support early career and new prostate cancer investigators. These programs will actively recruit and retain researchers from diverse backgrounds to foster cutting-edge and impactful prostate cancer translational science. We anticipate that the DF/HCC Prostate SPORE will make substantial scientific discoveries in the field and translate directly into benefits for men with prostate cancer.

项目概要-总体 丹娜-法伯/哈佛癌症中心（DF/HCC）前列腺孢子寻求提高理解 以及使用高度翻译的方法治疗前列腺癌。该应用程序包括三个 项目，三个核心，发展研究计划和职业提升计划。的 SPORE基础设施将促进我们蓬勃发展的基本社区内的互动和协作， 致力于前列腺癌研究的临床和人口科学研究人员。每个项目都涉及 这是导致前列腺癌发病率和死亡率的根本挑战。项目1利用 来自用新辅助疗法治疗的高危前列腺癌患者的肿瘤标本， 了解肿瘤如何响应和抵抗急性强效雄激素受体阻断，并开发新的 提高治愈率和抵抗力的战略。项目2将制定创新战略， 在晚期去势抵抗性前列腺癌的后期阶段的表观基因组，并将开发一个第一个在该领域 临床试验集中在共同靶向EZH 2和PARP。项目3深入研究生物标志物， 前列腺癌，利用计算和生物引导的深度学习方面的创新来实现 精准的癌症治疗能够理解为什么一些局限性前列腺 癌症是表型侵略性的，并预测哪些局限性前列腺癌将在这种情况下表现。 方式解决了大量临床未满足的需求。这些项目中的每一个都结合了优雅的临床前工作， 由DF/HCC研究者领导的创新临床研究。核心A，即行政核心，将成为 科学、财政和行政监督。它将领导规划和沟通方面的努力，并且还 病人权益保护委员会核心A将确保DF/HCC基础设施支持 开展临床和转化研究工作。核心B，生物统计学和计算生物学核心， 将提供生物统计学和管理基因组和其他下一代的专业知识， 测序数据和数据共享。核心C，生物标本和病理学核心，将保持组织/血液 存储库的孢子项目以及其他研究人员在前列腺癌计划。它将 提供关键的专业知识和病理学服务，包括下一代分子检测，并将帮助 促进新鲜肿瘤标本的使用，包括用于患者衍生模型开发的快速尸检 加快翻译研究发展研究和职业提升计划 将确定并资助创新项目，解决基础，转化和临床研究问题， 前列腺癌未满足的需求，并将支持早期职业和新的前列腺癌研究人员。这些 计划将积极招募和留住来自不同背景的研究人员，以培养尖端和 影响力前列腺癌转化科学我们预计DF/HCC前列腺孢子将使 该领域的重大科学发现，并直接转化为前列腺癌患者的益处。